Women who were postpartum with venous thromboembolism (VTE) or abnormal ECGs faced a substantially higher risk for pulmonary ...

Pulmonary arterial hypertension (PAH) is a rare and progressive condition caused by high blood pressure in the arteries that ...

Using nationwide networks, advanced cytokine profiling, and patient clustering, the team screened over 100 PAH patients to ...

Pharmaceuticals’ treatment of pulmonary arterial hypertension was granted FDA orphan designation status, according to a post to ...

Data showed that the expression (activity) of the ABCA3 gene was lower in IPAH patients, while that of the SMAD9 gene was ...

Patent covers brilaroxazine use for treating Pulmonary Fibrosis-Similar patents have also been granted in key markets around the world ...

Seborrheic dermatitis is linked to other epithelial barrier diseases, supporting the epithelial barrier theory as a shared ...

The landscape of coronary and pulmonary vascular medicine is undergoing a paradigm shift, fueled by breakthroughs in molecular biology, imaging, and ...

United Therapeutics has been on fire lately. In the past six months alone, the company’s stock price has rocketed 44.4%, ...

Anumana, a leader in AI-powered cardiovascular diagnostics, today announced new groundbreaking clinical data presented at the American Heart Association (AHA) Scientific Sessions 2025. Among the ...

Sotatercept (Winrevair; Merck) is enhancing treatment for patients with pulmonary arterial hypertension (PAH), explained ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension ...